Page 49 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

190. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates Ther Adv Med Oncol. 2020;12:1758835919897546.
ErbB2 and ErbB3 heterocomplex formation and function.
Oncogene. 2007;26(24):3503-3510. doi: 10.1177/1758835919897546
194. Belli S, Esposito D, Servetto A, Pesapane A, Formisano L,
doi: 10.1038/sj.onc.1210138
Bianco R. c-Src and EGFR inhibition in molecular cancer
191. Tryfonopoulos D, Walsh S, Collins DM, et al. Src: A potential therapy: What else can we improve? Cancers (Basel).
target for the treatment of triple-negative breast cancer. Ann 2020;12(6):1489.
Oncol. 2011;22(10):2234-2240.
doi: 10.3390/cancers12061489
doi: 10.1093/annonc/mdq757
195. Yoshida T, Zhang G, Smith MA, et al. Tyrosine
192. Finn RS, Dering J, Ginther C, et al. Dasatinib, an orally active phosphoproteomics identifies both codrivers and cotargeting
small molecule inhibitor of both the src and abl kinases, strategies for T790M-related EGFR-TKI resistance in non-
selectively inhibits growth of basal-type/”triple-negative” small cell lung cancer. Clin Cancer Res. 2014;20(15):4059-4074.
breast cancer cell lines growing in vitro. Breast Cancer Res
Treat. 2007;105(3):319-326. doi: 10.1158/1078-0432.Ccr-13-1559
doi: 10.1007/s10549-006-9463-x 196. Zhou Y, Yao Z, Lin Y, Zhang H. From tyrosine kinases to
tyrosine phosphatases: New therapeutic targets in cancers
193. Canonici A, Browne AL, Ibrahim MFK, et al. Combined
targeting EGFR and SRC as a potential novel therapeutic and beyond. Pharmaceutics. 2024;16(7):888.
approach for the treatment of triple negative breast cancer. doi: 10.3390/pharmaceutics16070888

Volume 2 Issue 3 (2025) 43 doi: 10.36922/IMO025200022